Medicinal drugs prototypes, innovative pharmaceutical production and search for medicines for Alzheimer - RUDN chemists open «Molecular design and synthesis of innovation compounds for medicine» scientific center
RUDN researchers are working together on heterocycle compounds to use them in medicine.
In December, «Molecular design and synthesis of innovation compounds for medicine» scientific center was opened. The Center is headed by professor Andrey Malkov (Loughborough University, Great Britain) and has already attracted chemists from Italy, India, China and Indonesia
RUDN researchers are looking for more efficient ways of producing more qualitative and cheaper products and synthesizing new substances including new biologically active compounds for medicine.
Viktor Khrustalev, Director of RUDN United Chemical Institute: «Currently we are on a fundamental stage. In our laboratory we can create prototypes for further testing and industrial production of substances for medicine and other fields».
RUDN researchers are working together with Italian colleagues from Bari University have already started a project on improving medicines for Alzheimer experimenting with nitrogen-containing heterocycle compounds and showing the possibility of more qualitative and cheaper product. In the laboratory some chemical reactions last 2-4 minutes instead of regular 3-4 days and are cleaner and safer.
Chemists will start with a precise mathematical model of the process using digital technologies, thus shortening the experimental period and increasing efficiency.
The Center is opened in the frame of 5-100 Project.
RUDN chemists have created a biodegradable polymer based on chitosan and polyhydroxybutyrate. Chitosan, which is obtained from animal shells and fungal cells, gives the compound antimicrobial properties, so it can be used for disposable medical and hygienic materials and products.
RUDN University professor together with colleagues from France and the USA has developed a technique for describing blood clotting regarding the individual characteristics of patients. This will help to make more accurately diagnosis and select drugs dosages for the treatment of haemophilia, thrombosis and other blood coagulation disorders.
RUDN chemists have proven the effectiveness of metal complexes for catalysis of cyanhydrin production — substances important for the chemical industry. Chemists managed to achieve 96.3% of the reaction efficiency.